Scroll

dapagliflozin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
sodium glucose co-transporter inhibitors, phlorizin derivatives	4304	461432-26-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dapagliflozin propanediol monohydrate dapagliflozin propanediol BMS 512148 forxiga dapaglifozin dapagliflozin farxiga dapagliflozin propylene glycolate hydrate	an Sodium-glucose cotransporter 2 (SGLT2) inhibitor, SGLT2 expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen, by inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion Molecular weight: 408.88 Formula: C21H25ClO6 CLOGP: 3.37 LIPINSKI: 0 HAC: 6 HDO: 4 TPSA: 99.38 ALOGS: -3.37 ROTB: 6 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dapagliflozin propanediol monohydrate
dapagliflozin propanediol
BMS 512148
forxiga
dapaglifozin
dapagliflozin
farxiga
dapagliflozin propylene glycolate hydrate

an Sodium-glucose cotransporter 2 (SGLT2) inhibitor, SGLT2 expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen, by inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion

Molecular weight: 408.88
Formula: C21H25ClO6
CLOGP: 3.37
LIPINSKI: 0
HAC: 6
HDO: 4
TPSA: 99.38
ALOGS: -3.37
ROTB: 6

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
CL (Clearance)	3 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	12.20 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	1.70 L/kg	Lombardo F, Berellini G, Obach RS
S (Water solubility)	1.60 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
fu (Fraction unbound in plasma)	0.09 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 6 of 6 entries

Previous1Next

Approvals:

Date	Agency	Company
Jan. 8, 2014	FDA	ASTRAZENECA AB
March 24, 2014	PMDA	BRISTOL-MYERS
Nov. 12, 2012	EMA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diabetic ketoacidosis	2955.92	18.32	773	18999	19732	63449518
Ketoacidosis	1348.86	18.32	305	19467	4073	63465177
Euglycaemic diabetic ketoacidosis	907.79	18.32	214	19558	3460	63465790
Fungal infection	347.03	18.32	187	19585	36687	63432563
Pruritus genital	237.24	18.32	69	19703	2585	63466665
Ketosis	223.09	18.32	49	19723	564	63468686
Blood glucose increased	184.76	18.32	175	19597	83581	63385669
Cardiospasm	181.22	18.32	52	19720	1855	63467395
Palmoplantar keratoderma	178.59	18.32	52	19720	1955	63467295
Diabetes mellitus inadequate control	165.77	18.32	85	19687	15041	63454209

Showing 1 to 10 of 149 entries

Previous1 2 3 4 5…15Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diabetic ketoacidosis	1995.35	16.73	655	22270	17377	34916629
Ketoacidosis	771.63	16.73	226	22699	4017	34929989
Euglycaemic diabetic ketoacidosis	726.71	16.73	203	22722	3019	34930987
Pruritus genital	234.66	16.73	78	22847	2126	34931880
Cardiospasm	208.97	16.73	66	22859	1522	34932484
Ketosis	206.98	16.73	51	22874	447	34933559
Palmoplantar keratoderma	191.62	16.73	65	22860	1888	34932118
Glycosylated haemoglobin increased	188.45	16.73	108	22817	11252	34922754
Metabolic acidosis	179.98	16.73	180	22745	43500	34890506
Sleep terror	176.97	16.73	64	22861	2254	34931752

Showing 1 to 10 of 162 entries

Previous1 2 3 4 5…17Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diabetic ketoacidosis	3818.17	15.54	1155	36332	32967	79673934
Ketoacidosis	1569.58	15.54	419	37068	7435	79699466
Euglycaemic diabetic ketoacidosis	1409.70	15.54	374	37113	6470	79700431
Pruritus genital	445.54	15.54	139	37348	4347	79702554
Cardiospasm	381.86	15.54	115	37372	3186	79703715
Palmoplantar keratoderma	364.25	15.54	114	37373	3602	79703299
Ketosis	352.41	15.54	86	37401	1040	79705861
Sleep terror	339.85	15.54	113	37374	4345	79702556
Atrial tachycardia	305.70	15.54	118	37369	7015	79699886
Metabolic acidosis	301.15	15.54	274	37213	82255	79624646

Showing 1 to 10 of 259 entries

Previous1 2 3 4 5…26Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A10BD15	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BD21	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BD25	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BK01	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sodium-glucose co-transporter 2 (SGLT2) inhibitors
CHEBI has role	CHEBI:35526	antidiabetic
CHEBI has role	CHEBI:73273	sodium-glucose transport protein subtype 2 inhibitors
FDA EPC	N0000187059	Sodium-Glucose Cotransporter 2 Inhibitor
FDA MoA	N0000187058	Sodium-Glucose Transporter 2 Inhibitors
MeSH PA	D007004	Hypoglycemic Agents
MeSH PA	D000077203	Sodium-Glucose Transporter 2 Inhibitors

Showing 1 to 10 of 10 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Diabetes mellitus type 1	indication	46635009	DOID:9744
Chronic heart failure	indication	48447003
Chronic kidney disease	indication	709044004

Showing 1 to 4 of 4 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.62	acidic
pKa2	13.26	acidic
pKa3	13.7	acidic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	9238076	April 15, 2024	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	8431685	April 13, 2025	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	8461105	April 13, 2025	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	7456254	June 30, 2025	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	6515117	Oct. 4, 2025	TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	6515117	Oct. 4, 2025	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	8329648	Aug. 18, 2026	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	8329648	Aug. 18, 2026	REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	8329648	Aug. 18, 2026	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	8906851	Aug. 18, 2026	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE

Showing 1 to 10 of 68 entries

Previous1 2 3 4 5 6 7Next

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	May 5, 2023	TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE (NYHA CLASS II-IV) WITH REDUCED EJECTION FRACTION
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	April 30, 2024	TO REDUCE THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
10MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	May 8, 2026	LABELING REVISIONS RELATED TO STUDY D1699CC00001
5MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	May 5, 2023	TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE (NYHA CLASS II-IV) WITH REDUCED EJECTION FRACTION
5MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	April 30, 2024	TO REDUCE THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG	FARXIGA	ASTRAZENECA AB	N202293	Jan. 8, 2014	RX	TABLET	ORAL	May 8, 2026	LABELING REVISIONS RELATED TO STUDY D1699CC00001

Showing 1 to 6 of 6 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium/glucose cotransporter 2	Transporter	P31639	SC5A2_HUMAN	INHIBITOR	IC50	9.30	IUPHAR	IUPHAR
Sodium/glucose cotransporter 1	Transporter	P13866	SC5A1_HUMAN		IC50	8.49	CHEMBL
Sodium/myo-inositol cotransporter 2	Transporter	Q8WWX8	SC5AB_HUMAN		IC50	6.42	CHEMBL
Low affinity sodium-glucose cotransporter	Transporter	Q9NY91	SC5A4_HUMAN		IC50	8.87	CHEMBL
Sodium/glucose cotransporter 2	Transporter		SC5A2_RAT		EC50	8.52	CHEMBL

Showing 1 to 5 of 5 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
014949	NDDF
014950	NDDF
1486966	RXNORM
1ULL0QJ8UC	UNII
210769	MMSL
28989	MMSL
29986	MMSL
4033035	VANDF
4594	IUPHAR_LIGAND_ID
703674001	SNOMEDCT_US

Showing 1 to 10 of 24 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
FARXIGA	HUMAN PRESCRIPTION DRUG LABEL	1	0310-6205	TABLET, FILM COATED	5 mg	ORAL	NDA	27 sections
FARXIGA	HUMAN PRESCRIPTION DRUG LABEL	1	0310-6205	TABLET, FILM COATED	5 mg	ORAL	NDA	27 sections
FARXIGA	HUMAN PRESCRIPTION DRUG LABEL	1	0310-6205	TABLET, FILM COATED	5 mg	ORAL	NDA	27 sections
FARXIGA	HUMAN PRESCRIPTION DRUG LABEL	1	0310-6210	TABLET, FILM COATED	10 mg	ORAL	NDA	27 sections
FARXIGA	HUMAN PRESCRIPTION DRUG LABEL	1	0310-6210	TABLET, FILM COATED	10 mg	ORAL	NDA	27 sections
FARXIGA	HUMAN PRESCRIPTION DRUG LABEL	1	0310-6210	TABLET, FILM COATED	10 mg	ORAL	NDA	27 sections
QTERN	HUMAN PRESCRIPTION DRUG LABEL	2	0310-6770	TABLET, FILM COATED	5 mg	ORAL	NDA	28 sections
QTERN	HUMAN PRESCRIPTION DRUG LABEL	2	0310-6770	TABLET, FILM COATED	5 mg	ORAL	NDA	28 sections
QTERN	HUMAN PRESCRIPTION DRUG LABEL	2	0310-6770	TABLET, FILM COATED	5 mg	ORAL	NDA	28 sections
QTERN	HUMAN PRESCRIPTION DRUG LABEL	2	0310-6780	TABLET, FILM COATED	10 mg	ORAL	NDA	28 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next